X

Drug Profile

Propofol - AstraZeneca/Aspen Pharmacare

Alternative Names: Diprivan

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class General anaesthetics; Phenols; Small molecules
Mechanism of Action GABA receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Sedation

Most Recent Events

07 Aug 2019 Launched for Sedation in Japan (IV)
18 Aug 2017 Aspen Pharmacare completed the transfer of Canadian commercialisation rights associated with propofol from AstraZeneca
06 Jun 2017 Propofol is under regulatory review for Sedation in Japan (IV) (AstraZeneca Annual Report 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com